Membrane breakdown in acute and chronic neurodegeneration: focus on choline-containing phospholipids.

Department of Pharmacology, University of Mainz, Federal Republic of Germany.
Journal of Neural Transmission (Impact Factor: 2.87). 02/2000; 107(8-9):1027-63. DOI: 10.1007/s007020070051
Source: PubMed

ABSTRACT Breakdown of cellular membranes is a characteristic feature of neuronal degeneration in acute (stroke) and chronic (senile dementia) neurological disorders. The present review summarizes recent experimental and clinical work which concentrated on changes of choline-containing phospholipids as indicators of neuronal membrane breakdown. Experimental studies identified glutamate release, calcium influx, and activation of cellular phospholipase A2 (PLA2) as important steps initiating membrane breakdown in cultured neurons or brain slices under hypoxic or ischemic conditions. Proton NMR studies have shown an elevation of choline-containing compounds in the brain of Alzheimer patients while neurochemical studies in post mortem-brain demonstrated increases of the catabolic metabolite, glycerophosphocholine, an indicator of PLA2 activation. In contrast, studies of cerebrospinal fluid, phosphorus NMR studies, and measurements of phospholipases in post mortem Alzheimer brain gave ambiguous results which may be explained by methodical limitations. The finding that, in experimental studies, choline was a rate-limiting factor for phospholipid biosynthesis has stimulated clinical studies aimed at counteracting phospholipid breakdown, e.g. by combinations of choline and cytidine. Future experimental approaches should clarify whether loss of membrane phospholipids is cause or consequence of the neurodegenerative disease process.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer's disease (AD) is a neurodegenerative disease that affects aging populations, with no effective method for its treatment to date. Elucidating the changes in biofluid small metabolite concentration during AD could improve both diagnosis and treatment. Ginsenosides Rg1 (GRg1) and Rb1 (GRb1), the pharmacologically active ingredients in ginseng, reportedly offer protection against AD symptoms, but the underlying mechanisms are unclear. These were investigated in the present study by examining the metabolite profiles of AD mice. The cognitive function of mice was tested in the Morris water maze and pathological changes to the brain were assessed by immunohistochemistry. Global metabolite profiling by ultra performance liquid chromatography/mass spectrometry and principal component analysis were carried out to identify metabolites that are differentially expressed in AD animals with or without ginsenosides treatment. A total of 10 potential biomarkers were identified that were associated with the metabolism of lecithin, amino acids, and sphingolipids in AD mice. The peak intensities of lysophosphatidylcholine, tryptophan, and dihydrosphingosine were lower, while that of phenylalanine was higher, in AD than in control mice. GRg1 treatment affected all three metabolic pathways, while GRb1 treatment affected lecithin and amino acid but not sphingolipid metabolism. These results provide the first evidence of a link between metabolite imbalance and AD, and reveal a molecular basis for the therapeutic benefits of ginsenosides in AD treatment. Copyright © 2015 Elsevier B.V. All rights reserved.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 01/2015; 985C:54-61. DOI:10.1016/j.jchromb.2015.01.016 · 2.69 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer’s disease (AD) is a progressive brain disease, for which there is no effective drug therapy at present. Ginsenoside Rg1 (G-Rg1) and Ginsenoside Rg2 (G-Rg2) have been reported to alleviate memory deterioration. However, the mechanism of their anti-AD effect hasn’t yet been clearly elucidated.
    Journal of ginseng research 04/2015; DOI:10.1016/j.jgr.2015.04.006 · 2.30 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This study aimed to examine the effect of pea fiber (PF) and wheat bran fiber (WF) supplementation in rat metabolism. Rats were assigned randomly to one of three dietary groups and were given a basal diet containing 15% PF, 15% WF, or no supplemental fiber. Urine and plasma samples were analyzed by NMR-based metabolomics. PF significantly increased the plasma levels of 3-hydroxybutyrate, and myo-inositol as well as the urine levels of alanine, hydroxyphenylacetate, phenylacetyglycine, and α-ketoglutarate. However, PF significantly decreased the plasma levels of isoleucine, leucine, lactate, and pyruvate as well as the urine levels of allantoin, bile acids, and trigonelline. WF significantly increased the plasma levels of acetone, isobutyrate, lactate, myo-inositol, and lipids as well as the urine levels of alanine, lactate, dimethylglycine, N-methylniconamide, and α-ketoglutarate. However, WF significantly decreased the plasma levels of amino acids, and glucose as well as the urine levels of acetate, allantoin, citrate, creatine, hippurate, hydroxyphenylacetate, and trigonelline. Results suggest that PF and WF exposure can promote antioxidant activity and can exhibit common systemic metabolic changes, including lipid metabolism, energy metabolism, glycogenolysis and glycolysis metabolism, protein biosynthesis, and gut microbiota metabolism. PF can also decrease bile acid metabolism. These findings indicate that different fiber diet may cause differences in the biofluid profile in rats.
    PLoS ONE 12/2014; 9(12):e115561. DOI:10.1371/journal.pone.0115561 · 3.53 Impact Factor